Lencer, R
Mills, L J
Alliey-Rodriguez, N
Shafee, R
Lee, A M
Reilly, J L
Sprenger, A http://orcid.org/0000-0001-9255-7911
McDowell, J E
McCarroll, S A
Keshavan, M S
Pearlson, G D
Tamminga, C A
Clementz, B A
Gershon, E S
Sweeney, J A
Bishop, J R
Article History
Received: 10 July 2017
Accepted: 14 July 2017
First Online: 24 October 2017
Competing interests
: CAT reports the following financial disclosures: American Psychiatric Association, Deputy Editor; Astellas, Ad Hoc Consultant; Autifony, Ad Hoc Consultant; The Brain and Behavior Foundation, Council Member; Eli Lilly Pharmaceuticals, Ad Hoc Consultant; Intra-cellular Therapies (ITI), Advisory Board, drug development; Institute of Medicine, Council Member; National Academy of Medicine, Council Member; Pfizer, Ad Hoc Consultant; Sunovion, Investigator Initiated grant funding. JAS reports the following financial disclosures: ad hoc consultant to Takeda Pharmaceuticals. The remaining authors declare no conflict of interest.